The purpose of the study was to examine the indicators of lipid and energy metabolism in patients with acute myocardial infarction in the presence or absence of type 2 diabetes mellitus. Materials and methods. A total of 134 patients with acute ST-segment elevation myocardial infarction in the presence or absence of type 2 diabetes mellitus aged 58.97 ± 7.92 years were examined on the basis of the Intensive Care Department at the Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” and the Kharkiv Railway Clinical Hospital No. 1 of the branch “Center of Healthcare” of Public Joint Stock Company “Ukrainian Railway”. Group 1 consisted of 74 patients with acute myocardial infarction and type 2 diabetes mellitus aged 59.42 ± 7.66 years. Group 2 (comparison group) included 60 patients with acute myocardial infarction without type 2 diabetes mellitus aged 58.42 ± 8.25 years. The control group comprised of 20 healthy individuals. All the patients of groups 1 and 2 underwent percutaneous coronary intervention. The study was conducted from September 1, 2018 to December 31, 2020. Serum concentration of adropin and irisin in patients was determined by enzyme-linked immunosorbent assay. Total cholesterol and high-density lipoprotein cholesterol in serum were measured by peroxidase enzymatic method. Triglyceride levels were analyzed by enzymatic colorimetric method. The atherogenic index was calculated by A. M. Klimov formula. Very low-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels were estimated by the Friedewald formula. Results and discussion. Group 1 patients were found to have higher serum triglyceride levels compared with group 2 patients (p<0.05). In groups 1 and 2, total cholesterol and low-density lipoprotein cholesterol levels presented an upward tendency (p˃0.05), and very low-density lipoprotein cholesterol levels were significantly by 4.04 and 2.92 times increased, respectively, as compared to the control group (p<0.05). The serum adropin levels were significantly lower in patients with acute myocardial infarction and type 2 diabetes mellitus in comparison to those in patients with acute myocardial infarction without type 2 diabetes mellitus (p<0.05). There was a significant decrease in the concentrations of adropin and irisin in both groups compared with the control group (p<0.05). Conclusion. Characteristics of changes in adropin and irisin levels suggest an energy homeostasis imbalance in acute myocardial infarction in the presence or absence of type 2 diabetes mellitus that may significantly increase the risk of cardiovascular complications of acute myocardial infarction in this category of patients. The relationship between adropin, irisin and lipid profile may indicate the influence of these markers on lipid metabolism

Keywords: markers, energy and lipid metabolism, acute myocardial infarction, type 2 diabetes mellitus

Full text: PDF (Ukr) 250K

1. Cui J, Liu Y, Li Y, Xu F, Liu Y. Type 2 diabetes and myocardial infarction: recent clinical evidence and perspective. Front Cardiovasc Med. 2021;8:644189. PMID: 33718461. PMCID: PMC7943438. https://doi.org/10.3389/fcvm.2021.644189
2. Newsletter Top 10 causes of death in the world. WHO. December 9, 2020. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
3. Pasiyeshvili LM, Marchenko AS, Zagrebelska AV, Malyk NV, Karaya OV. Rol ozhyrinnya ta osoblyvostey topografiyi zhyrovoyi tkanyny v perebigu tsukrovogo diabet u 2-go typu [The role of obesity and features of adipose tissue topography in the course of diabetes mellitus in type 2]. Zdobutky klinichnoyi i eksperymentalnoyi medytsyny. 2021;4:147-150. [Ukrainian]. https://doi.org/10.11603/1811-2471.2021.v.i4.12480
4. Ma X, Sun Y, Cheng Y, Shen H, Gao F, Qi J, et al. Prognostic impact of the atherogenic index of plasma in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention. Lipids Health Dis. 2020;19:240. PMID: 33198752. PMCID: PMC7667811. https://doi.org/10.1186/s12944-020-01418-0
5. Tahir A, Martinez PJ, Ahmad F, Fisher-Hoch SP, McCormick J, Gay JL, et al. An evaluation of lipid profile and pro inflammatory cytokines as determinants of cardiovascular disease in those with diabetes: a study on a Mexican American cohort. Sci Rep. 2021;11:2435. PMID: 33510184. PMCID: PMC7844256. https://doi.org/10.1038/s41598-021-81730-6
6. Marczuk N, Cecerska-Heryć E, Jesionowska A, Dołęgowska B. Adropin - physiological and pathophysiological role. Postepy Hig Med Dosw. 2016;70(0):981-988. PMID: 27668650. https://doi.org/10.5604/17322693.1220082
7. Huh JY. The role of exercise-induced myokines in regulating metabolism. Arch Pharm Res. 2018;41(1):14-29. PMID: 29177585. https://doi.org/10.1007/s12272-017-0994-y
8. Yu HY, Zhao P, Wu MC, Liu J, Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 2014;190-191:46-49. PMID: 24731968. https://doi.org/10.1016/j.regpep.2014.04.001
9. Askin L, Uzel KE, Tanriverdi O, Turkmen S. Serum irisin: pathogenesis and clinical research in cardiovascular diseases. Cardiovasc Innov Appl. 2020;4(3):195-200. https://doi.org/10.15212/cvia.2019.0569
10. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. PMID: 28886621. https://doi.org/10.1093/eurheartj/ehx393
11. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. PMID: 31497854. https://doi.org/10.1093/eurheartj/ehz486
12. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498. PMID: 30288571. https://doi.org/10.1007/s00125-018-4729-5
13. Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes. 2014;63:3242-3252. PMID: 24848071. PMCID: PMC4171656. https://doi.org/10.2337/db14-0388
14. Mushala BAS, Scott I. Adropin: a hepatokine modulator of vascular function and cardiac fuel metabolism. Am J Physiol Heart Circ Physiol. 2021;320:H238-H244. PMID: 33216612. PMCID: PMC7847067. https://doi.org/10.1152/ajpheart.00449.2020
15. Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci. 2018;19(5):1293. PMID: 29701665. PMCID: PMC5983814. https://doi.org/10.3390/ijms19051293
16. Khidr EG, Ali SS, Elshafey MM, Fawzy OA. Association of irisin and FNDC5 rs16835198 G > T gene polymorphism with type 2 diabetes mellitus and diabetic nephropathy. An Egyptian pilot study. Gene. 2017;626:26-31. PMID: 28479383. https://doi.org/10.1016/j.gene.2017.05.010
17. Assyov Y, Gateva A, Tsakova A, Kamenov Z. Irisin in the Glucose Continuum. Exp Clin Endocrinol Diabetes. 2015;124(1):22-27. PMID: 26479549. https://doi.org/10.1055/s-0035-1564130
18. Anastasilakis AD, Koulaxis D, Kefala N, Polyzos SA, Upadhyay J, Pagkalidou E, et al. Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism. 2017;73:1-8. PMID: 28732565. https://doi.org/10.1016/j.metabol.2017.05.002